Effects of fasudil on isoproterenol induced cardiac hypertrophy in rats

doi:10.13459/j.cnki.cjap.2016.05.008

Abstract

Abstract: Objective: To investigate the effects and mechanisms of fasudil (Fas) on cardiac hypertrophy (CH) induced by isoprenaline(Iso) in rats. Methods: Except for the normal control group, the rest three groups rats were injected subcutaneously with Iso(5mg/kg) for setting up CH model. SD rats were randomly divided into four groups:Normal control group, Iso model group, Fas with low-dose group (5 mg/kg, i.p) and Fas with high-dose group (20 mg/kg, i.p). Animals were treated with Fas for 8 weeks. After the treatment, the following index were detected:heart rate (HR), left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), left ventricular systolic maximum rate (+dp/dt_max) and left ventricular diastolic maximum rate (-dp/dt_max). The body weight(BW) and heart weight (HW) were weighed and heart weight index (HWI) was calculateed. Myocardial tissue specimens, HE and Masson staining were performed for observing the histopathological changes. The protein expression of extracellular signal-regulated kinase 1/2 (ERK1/2) in myocardial tissue was determined by using immunohistochemical methods. The expression of ERK1/2 mRNA in the myocardial tissue was detected by using semi-quantitative RT-PCR method. Results: Compared with normal control group, HR and LVEDP wereincreased significantly, while LVSP and ±dp/dtmax were decreased significantly; HWI was increased significantly in CH group; The myocardial cell volume and the cell gap were increased,cells arranged disorder, and severe myocardial interstitial fibrosis was presented in CH group. The expression of ERK1/2 mRNA was significantly increased. After Fas treatment, the systolic and diastolic functions of heart were improved, cell volume was reduced, cell gap became small, cells arranged in neat rows, and the fibrosis was significantly reduced. The expressions of RhoA, ERK1/2 mRNA were significantly reduced. The damages of myocardial tissue were improved in different degrees. Conclusion: ERK1/2 signaling pathway is involved in Iso induced CH. Fas protects against the CH of rats induced by Iso, which mechanisms may be related with blocking ERK1/2 signaling pathway.

Key words: isoproterenol, ERK1/2, fasudil, myocardial hypertrophy, rats

CHENG Jie-kun, SUN Xiao-hui, GAO Li-ping, LI Le. Effects of fasudil on isoproterenol induced cardiac hypertrophy in rats[J]. CJAP, 2016, 32(5): 414-418.

References

[1] Hughes SE. The pathology of hypertrophic cardiomyopathy[J]. Histopathology, 2004, 44(5):412-427.
[2] Zhang L, Mmagu O, Liu L, et al. Hypertrophic cardiomyopathy:Can thenoninvasive diagnostic testing identify high risk patients[J]. World J Cardiol, 2014, 6(8):764-770.
[3] Bauml MA, Underwood DA. Left ventricular hypertrophy:an overlooked cardiovascular risk factor[J]. Cleve Clin J Med, 2010, 77(6):381-387.
[4] Schilling M, Maiwald T, Hengl S, et al. Theoretical and experimentalanalysis links isoform-specific ERK signalling to cell fate decisions[J]. Mol Syst Biol, 2009, 5:334.
[5] 刘冬梅, 王洪新, 张蕾, 等. κ-阿片受体激动对高糖诱导心肌肥大的影响[J]. 中国应用生理学杂志, 2010, 26(4):463-465.
[6] Shi J, Wei L. Rho kinases in cardiovascular physiology and pathophysiology:the effect of fasudil[J]. J Cardiovasc Pharmacol, 2013, 62(4):341-354.
[7] Parthasarathy A, Gopi V, Devi KM S, et al. Aminoguanidine inhibits ventricular fibrosis and remodeling process in isoproterenol-induced hypertrophied rat hearts by suppressing ROS and MMPs[J]. Life Sci, 2014, 118(1):15-26.
[8] Miyoshi T, Nakamura K, Yoshida M, et al. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats[J]. Cardiovasc Diabetol, 2014, 13:43.
[9] Sturm OE, Orton R, Grindlay J, et al. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier[J]. SCI Signal, 2010, 3(153):ra90.
[10] 吴扬, 顾玉梅. 银杏叶提取物和槲皮素对心肌细胞肥大的防治作用及其机制[J]. 中国应用生理学杂志, 2007, 23(2):138-142.
[11] Liu YL, Huang CC, Chang CC, et al. Hyperphosphate-induced myocardial hypertrophy through the GATA-4/NFAT-3 signaling pathway is attenuated by ERK inhibitor treatment[J]. Cardiorenal Med, 2015, 5(2):79-88.
[12] Guo H, Liu B, Hou L, et al. The role of mAKAPβ in the process of cardiomyocyte hypertrophy induced by angiotensin Ⅱ[J]. Int J Mol Med, 2015, 35(5):1159-1168.
[13] Wang N, Guan P, Zhang JP, et al. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproterenol-induced heart failure in rats via JNK and ERK1/2 pathways[J]. J Cell Biochem, 2011, 112(7):1920-1929.
[14] Roskoski R Jr. ERK1/2 MAP kinases:structure, function, and regulation[J]. Pharmacol Res, 2012, 66(2):105-143.
[15] Zhang Q, Wang H, Yang YJ, et al. Atorvastatin treatment improves the effects of mesenchymal stem cell transplantation on acute myocardial infarction:Therole of the RhoA/ROCK/ERK pathway[J]. Int J Cardiol, 2014, 176(3):670-679.
[16] Merla R, Ye Y, Lin Y, et al. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation[J]. Am J Physiol-Heart Circ Physiol, 2007, 293(3):H1918-1928.
[17] Xu X, Zhang L, Liang J. Rosuvastatin prevents pressure overload-induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats[J]. Mol Med Rep, 2013, 8(2):385-392.
[18] Takayama N, Kai H, Kudo H, et al. Simvastatin prevents largeblood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats byinhibiting RhoA/Ras ERK pathways[J]. Hypertens Res, 2011, 34(3):341-347.
[19] Liu AJ, Ling F, Wang D, et al. Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip' via the ERK signal pathway[J]. Chin Med J, 2011, 124(19):3098-3104.
[20] Ho TJ, Huang CC, Huang CY, et al. Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy,apoptosis and fibrosis in rats[J]. Eur J Appl Physiol, 2012, 112(8):2943-2955.
[21] Kehat I, Davis J, Tiburcy M, et al. Extracellular signal-regulated kinases1 and 2 regulate the balance between eccentric and concentric cardiac growth[J]. Circ Res, 2011, 108(2):176-183.